Metabolic syndrome and renal cell carcinoma

World Journal of Surgical Oncology

Ding-Wei Ye¹  Yao Zhu²  Gui-Ming Zhang² 

[1] Department of Urology, Fudan University Shanghai Cancer Center, No. 270, Dongan Rd, Shanghai 200032, China;Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

关键词: Mechanism;    Insulin resistance;    Renal cell carcinoma;    Metabolic syndrome;   

Others  :  1148497
DOI  :  10.1186/1477-7819-12-236

 received in 2013-10-27, accepted in 2014-07-20,  发布年份 2014

【 摘 要 】

Background

Metabolic syndrome (MS) is a cluster of metabolic abnormalities, which has been regarded as a pivotal risk factor for cardiovascular diseases. Recent studies focusing on the relationship between MS and cancer have recognized the significant role of MS on carcinogenesis. Likewise, growing evidence suggests that MS has a strong association with increased renal cell carcinoma (RCC) risk. This review outlines the link between MS and RCC, and some underlying mechanisms responsible for MS-associated RCC.

Materials and methods

A National Center for Biotechnology Information PubMed search (http://www.pubmed.gov webcite) was conducted using medical subject headings ‘metabolic syndrome’, ‘obesity’, ‘hypertension’, ‘diabetes’, ‘dyslipidemia’, and ‘renal cell carcinoma’.

Results

This revealed that a variety of molecular mechanisms secondary to MS are involved in RCC formation, progression, and metastasis. A deeper understanding of these molecular mechanisms may provide some strategies for the prevention and treatment of RCC.

Conclusions

In summary, there is a large body of evidence regarding the link between MS and RCC, within which each component of MS is considered to have a close causal association with RCC.

【 授权许可】

   
2014 Zhang et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Ford ES, Li C, Zhao G: Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes 2010, 2:180-193.
• [2]Zanchetti A, Hennig M, Baurecht H, Tang R, Cuspidi C, Carugo S, Mancia G: Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. J Hypertens 2007, 25:2463-2470.
• [3]Escobedo J, Schargrodsky H, Champagne B, Silva H, Boissonnet CP, Vinueza R, Torres M, Hernandez R, Wilson E: Prevalence of the metabolic syndrome in Latin America and its association with sub-clinical carotid atherosclerosis: the CARMELA cross sectional study. Cardiovasc Diabetol 2009, 8:52.
• [4]Thomas GN, Ho SY, Janus ED, Lam KS, Hedley AJ, Lam TH, Hong Kong Cardiovascular Risk Factor Prevalence Study Steering C: The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) prevalence of the metabolic syndrome in a Chinese population. Diabetes Res Clin Pract 2005, 67:251-257.
• [5]Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
• [6]Turati F, Talamini R, Pelucchi C, Polesel J, Franceschi S, Crispo A, Izzo F, La Vecchia C, Boffetta P, Montella M: Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer 2013, 108:222-228.
• [7]Wu Q, Chen G, Wu WM, Zhou L, You L, Zhang TP, Zhao YP: Metabolic syndrome components and risk factors for pancreatic adenocarcinoma: a case–control study in China. Digestion 2012, 86:294-301.
• [8]Lindkvist B, Almquist M, Bjorge T, Stocks T, Borena W, Johansen D, Hallmans G, Engeland A, Nagel G, Jonsson H, Selmer R, Diem G, Haggstrom C, Tretli S, Stattin P, Manjer J: Prospective cohort study of metabolic risk factors and gastric adenocarcinoma risk in the Metabolic Syndrome and Cancer Project (Me-Can). Cancer Causes Control 2013, 24:107-116.
• [9]Forootan M, Tabatabaeefar M, Yahyaei M, Maghsoodi N: Metabolic syndrome and colorectal cancer: a cross-sectional survey. Asian Pac J Cancer Prev 2012, 13:4999-5002.
• [10]Haggstrom C, Stocks T, Rapp K, Bjorge T, Lindkvist B, Concin H, Engeland A, Manjer J, Ulmer H, Selmer R, Tretli S, Hallmans G, Jonsson H, Stattin P: Metabolic syndrome and risk of bladder cancer: prospective cohort study in the metabolic syndrome and cancer project (Me-Can). Int J Cancer 2011, 128:1890-1898.
• [11]Hammarsten J, Peeker R: Urological aspects of the metabolic syndrome. Nat Rev Urol 2011, 8:483-494.
• [12]Shou HF, Ni J, Zhu T, Chen JH, Zhang X, Xu XX, Chen L, Yu H: Association between endometrial cancer and metabolic syndrome. Chin J Obstet Gynecol 2010, 45:128-131.
• [13]Penaranda EK, Shokar N, Ortiz M: Relationship between Metabolic Syndrome and History of Cervical Cancer among a US National Population. ISRN Oncol 2013, 2013:840964.
• [14]Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Rafaniello C, Giugliano D: Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis. Menopause 2013, 12:1301-1309.
• [15]Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D: Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 2012, 35:2402-2411.
• [16]Buschemeyer WC 3rd, Freedland SJ: Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 2007, 52:331-343.
• [17]Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA: Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control 2010, 21:61-68.
• [18]Shen Z, Ye Y, Bin L, Yin M, Yang X, Jiang K, Wang S: Metabolic syndrome is an important factor for the evolution of prognosis of colorectal cancer: survival, recurrence, and liver metastasis. Am J Surg 2010, 200:59-63.
• [19]Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, Panico S: Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 2006, 119:236-238.
• [20]Han RF, Sun BC, Yao Z: Kidney cancer. Beijing: People’s Medical Publishing House; 2010.
• [21]Chow WH, Gridley G, Fraumeni JF Jr, Jarvholm B: Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 2000, 343:1305-1311.
• [22]Bergstrom A, Hsieh CC, Lindblad P, Lu CM, Cook NR, Wolk A: Obesity and renal cell cancer–a quantitative review. Br J Cancer 2001, 85:984-990.
• [23]Leiba A, Kark JD, Afek A, Derazne E, Barchana M, Tzur D, Vivante A, Shamiss A: Adolescent obesity and paternal country of origin predict renal cell carcinoma: a cohort study of 1.1 million 16 to 19-year-old males. J Urol 2013, 189:25-29.
• [24]Waalkes S, Merseburger AS, Kramer MW, Herrmann TR, Wegener G, Rustemeier J, Hofmann R, Schrader M, Kuczyk MA, Schrader AJ: Obesity is associated with improved survival in patients with organ-confined clear-cell kidney cancer. Cancer Causes Control 2010, 21:1905-1910.
• [25]Rogde AJ, Gudbrandsdottir G, Hjelle KM, Sand KE, Bostad L, Beisland C: Obesity is associated with an improved cancer-specific survival, but an increased rate of postoperative complications after surgery for renal cell carcinoma. Scand J Urol Nephrol 2012, 46:348-357.
• [26]Zhu Y, Wang HK, Zhang HL, Yao XD, Zhang SL, Dai B, Shen YJ, Liu XH, Zhou LP, Ye DW: Visceral obesity and risk of high grade disease in clinical t1a renal cell carcinoma. J Urol 2013, 189:447-453.
• [27]Steffens S, Grunwald V, Ringe KI, Seidel C, Eggers H, Schrader M, Wacker F, Kuczyk MA, Schrader AJ: Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy? Oncologist 2011, 16:1565-1571.
• [28]Colt JS, Schwartz K, Graubard BI, Davis F, Ruterbusch J, DiGaetano R, Purdue M, Rothman N, Wacholder S, Chow WH: Hypertension and risk of renal cell carcinoma among white and black Americans. Epidemiology 2011, 22:797-804.
• [29]Wang G, Hou J, Ma L, Xie J, Yin J, Xu D, Chang W, Tan X, Su T, Zhang H, Cao G: Risk factor for clear cell renal cell carcinoma in Chinese population: a case–control study. Cancer Epidemiol 2012, 36:177-182.
• [30]Grossman E, Messerli FH, Goldbourt U: Does diuretic therapy increase the risk of renal cell carcinoma? Am J Cardiol 1999, 83:1090-1093.
• [31]Corrao G, Scotti L, Bagnardi V, Sega R: Hypertension, antihypertensive therapy and renal-cell cancer: a meta-analysis. Curr Drug Saf 2007, 2:125-133.
• [32]Lindblad P, Chow WH, Chan J, Bergstrom A, Wolk A, Gridley G, McLaughlin JK, Nyren O, Adami HO: The role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologia 1999, 42:107-112.
• [33]Joh HK, Willett WC, Cho E: Type 2 diabetes and the risk of renal cell cancer in women. Diabetes Care 2011, 34:1552-1556.
• [34]Li M, Liu J, Hu WL, Jia CH, Li HY, Wen ZH, Zou ZP, Bai XC, Luo SQ: Effect of metformin on apoptosis of renal cell carcinoma cells in vitro and its mechanisms. Nan Fang Yi Ke Da Xue Xue Bao 2011, 31:1504-1508.
• [35]Liu J, Li M, Song B, Jia C, Zhang L, Bai X, Hu W: Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urol Oncol 2013, 31:264-270.
• [36]Wulaningsih W, Garmo H, Holmberg L, Hammar N, Jungner I, Walldius G, Van Hemelrijck M: Serum Lipids and the Risk of Gastrointestinal Malignancies in the Swedish AMORIS Study. J Cancer Epidemiol 2012, 2012:792034.
• [37]Inoue M, Noda M, Kurahashi N, Iwasaki M, Sasazuki S, Iso H, Tsugane S: Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev 2009, 18:240-247.
• [38]Magura L, Blanchard R, Hope B, Beal JR, Schwartz GG, Sahmoun AE: Hypercholesterolemia and prostate cancer: a hospital-based case–control study. Cancer Causes Control 2008, 19:1259-1266.
• [39]Pothiwala P, Jain SK, Yaturu S: Metabolic syndrome and cancer. Metab Syndr Relat Disord 2009, 7:279-288.
• [40]Kucharska-Newton AM, Rosamond WD, Mink PJ, Alberg AJ, Shahar E, Folsom AR: HDL-cholesterol and incidence of breast cancer in the ARIC cohort study. Ann Epidemiol 2008, 18:671-677.
• [41]Lim U, Gayles T, Katki HA, Stolzenberg-Solomon R, Weinstein SJ, Pietinen P, Taylor PR, Virtamo J, Albanes D: Serum high-density lipoprotein cholesterol and risk of non-hodgkin lymphoma. Cancer Res 2007, 67:5569-5574.
• [42]Van Hemelrijck M, Garmo H, Hammar N, Jungner I, Walldius G, Lambe M, Holmberg L: The interplay between lipid profiles, glucose, BMI and risk of kidney cancer in the Swedish AMORIS study. Int J Cancer 2012, 130:2118-2128.
• [43]Ahn J, Lim U, Weinstein SJ, Schatzkin A, Hayes RB, Virtamo J, Albanes D: Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomarkers Prev 2009, 18:2814-2821.
• [44]Horiguchi A, Ito K, Sumitomo M, Kimura F, Asano T, Hayakawa M: Decreased serum adiponectin levels in patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 2008, 38:106-111.
• [45]Rasmuson T, Grankvist K, Jacobsen J, Olsson T, Ljungberg B: Serum insulin-like growth factor-1 is an independent predictor of prognosis in patients with renal cell carcinoma. Acta Oncol 2004, 43:744-748.
• [46]Rosendahl AH, Forsberg G: IGF-I and IGFBP-3 augment transforming growth factor-beta actions in human renal carcinoma cells. Kidney Int 2006, 70:1584-1590.
• [47]Ibrahim YH, Yee D: Insulin-like growth factor-I and cancer risk. Growth Horm IGF Res 2004, 14:261-269.
• [48]Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA: Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004, 56:549-580.
• [49]Li Y, Zhong YB, Lu L, Chen C, Duan CM: Research progress of insulin-like growth factor binding protein-3. Periodical of Ocean University of China 2011, 41:41-47.
• [50]Major JM, Pollak MN, Snyder K, Virtamo J, Albanes D: Insulin-like growth factors and risk of kidney cancer in men. Br J Cancer 2010, 103:132-135.
• [51]Chuang ST, Patton KT, Schafernak KT, Papavero V, Lin F, Baxter RC, Teh BT, Yang XJ: Over expression of insulin-like growth factor binding protein 3 in clear cell renal cell carcinoma. J Urol 2008, 179:445-449.
• [52]Cardillo MR, Ippoliti F: Interleukin-6, interleukin-10 and heat shock protein-90 expression in renal epithelial neoplasias and surrounding normal-appearing renal parenchyma. Int J Immunopathol Pharmacol 2007, 20:37-46.
• [53]Zinman B, Hanley AJ, Harris SB, Kwan J, Fantus IG: Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab 1999, 84:272-278.
• [54]Ho MY, Tang SJ, Chuang MJ, Cha TL, Li JY, Sun GH, Sun KH: TNF-alpha induces epithelial-mesenchymal transition of renal cell carcinoma cells via a GSK3beta-dependent mechanism. Mol Cancer Res 2012, 10:1109-1119.
• [55]Ambrose M, Ryan A, O’Sullivan GC, Dunne C, Barry OP: Induction of apoptosis in renal cell carcinoma by reactive oxygen species: involvement of extracellular signal-regulated kinase 1/2, p38delta/gamma, cyclooxygenase-2 down-regulation, and translocation of apoptosis-inducing factor. Mol Pharmacol 2006, 69:1879-1890.
• [56]Li J, Wang G, Chu Y, Rong R, Zhu T: The clinical application of COX-2 inhibitors may strengthen the sensitivity of renal cell carcinoma to immunotherapy. Med Hypotheses 2008, 71:527-529.
• [57]Chang BD, Cao LS, Zhou HL: Expression of COX-2 and VEGF and their correlation with angiogenesis in human clear cell renal cell carcinoma. Zhonghua Zhong Liu Za Zhi 2009, 31:687-690.
• [58]Sun H, Wang H, Qin WJ, Yang B, Wang SC, Jian BL: Expression of IGF-IR and COX-2 in renal cell carcinoma and their relationship with cell proliferation. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2009, 25:348-350.
• [59]Kankuri-Tammilehto MK, Soderstrom KO, Pelliniemi TT, Vahlberg T, Pyrhonen SO, Salminen EK: Prognostic evaluation of COX-2 expression in renal cell carcinoma. Anticancer Res 2010, 30:3023-3030.
• [60]Wang X, Zhang L, O’Neill A, Bahamon B, Alsop DC, Mier JW, Goldberg SN, Signoretti S, Atkins MB, Wood CG, Bhatt RS: Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts. Br J Cancer 2013, 108:319-326.
• [61]Gavrila A, Chan JL, Yiannakouris N, Kontogianni M, Miller LC, Orlova C, Mantzoros CS: Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metab 2003, 88:4823-4831.
• [62]Coppola A, Marfella R, Coppola L, Tagliamonte E, Fontana D, Liguori E, Cirillo T, Cafiero M, Natale S, Astarita C: Effect of weight loss on coronary circulation and adiponectin levels in obese women. Int J Cardiol 2009, 134:414-416.
• [63]Ukkola O, Santaniemi M: Adiponectin: a link between excess adiposity and associated comorbidities? J Mol Med (Berl) 2002, 80:696-702.
• [64]Spyridopoulos TN, Petridou ET, Skalkidou A, Dessypris N, Chrousos GP, Mantzoros CS: Low adiponectin levels are associated with renal cell carcinoma: a case–control study. Int J Cancer 2007, 120:1573-1578.
• [65]Pinthus JH, Kleinmann N, Tisdale B, Chatterjee S, Lu JP, Gillis A, Hamlet T, Singh G, Farrokhyar F, Kapoor A: Lower plasma adiponectin levels are associated with larger tumor size and metastasis in clear-cell carcinoma of the kidney. Eur Urol 2008, 54:866-873.
• [66]Sugiyama M, Takahashi H, Hosono K, Endo H, Kato S, Yoneda K, Nozaki Y, Fujita K, Yoneda M, Wada K, Nakagama H, Nakajima A: Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int J Oncol 2009, 34:339-344.
• [67]Brakenhielm E, Veitonmaki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, Funahashi T, Cao Y: Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A 2004, 101:2476-2481.
• [68]Margetic S, Gazzola C, Pegg GG, Hill RA: Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 2002, 26:1407-1433.
• [69]Horiguchi A, Sumitomo M, Asakuma J, Asano T, Zheng R, Asano T, Nanus DM, Hayakawa M: Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinoma. J Urol 2006, 176:1631-1635.
• [70]Horiguchi A, Sumitomo M, Asakuma J, Asano T, Zheng R, Asano T, Nanus DM, Hayakawa M: Leptin promotes invasiveness of murine renal cancer cells via extracellular signal-regulated kinases and rho dependent pathway. J Urol 2006, 176:1636-1641.
• [71]Li L, Gao Y, Zhang LL, He DL: Concomitant activation of the JAK/STAT3 and ERK1/2 signaling is involved in leptin-mediated proliferation of renal cell carcinoma Caki-2 cells. Cancer Biol Ther 2008, 7:1787-1792.
• [72]Gonzalez-Perez RR, Xu Y, Guo S, Watters A, Zhou W, Leibovich SJ: Leptin upregulates VEGF in breast cancer via canonic and non-canonical signalling pathways and NFkappaB/HIF-1alpha activation. Cell Signal 2010, 22:1350-1362.
• [73]Inoue K, Kawahito Y, Tsubouchi Y, Kohno M, Yoshimura R, Yoshikawa T, Sano H: Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. Biochem Biophys Res Commun 2001, 287:727-732.
• [74]Yang FG, Zhang ZW, Xin DQ, Shi CJ, Wu JP, Guo YL, Guan YF: Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines. Acta Pharmacol Sin 2005, 26:753-761.
• [75]Yuan J, Takahashi A, Masumori N, Uchida K, Hisasue S, Kitamura H, Itoh N, Tsukamoto T: Ligands for peroxisome proliferator-activated receptor gamma have potent antitumor effect against human renal cell carcinoma. Urology 2005, 65:594-599.
• [76]Fujita M, Tohji C, Honda Y, Yamamoto Y, Nakamura T, Yagami T, Yamamori M, Okamura N: Cytotoxicity of 15-deoxy-Delta (12,14)-prostaglandin J (2) through PPARgamma-independent pathway and the involvement of the JNK and Akt pathway in renal cell carcinoma. Int J Med Sci 2012, 9:555-566.
• [77]Pasarica M, Sereda OR, Redman LM, Albarado DC, Hymel DT, Roan LE, Rood JC, Burk DH, Smith SR: Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes 2009, 58:718-725.
• [78]Wang B, Wood IS, Trayhurn P: Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch 2007, 455:479-492.
• [79]Gunton JE, Kulkarni RN, Yim S, Okada T, Hawthorne WJ, Tseng YH, Roberson RS, Ricordi C, O’Connell PJ, Gonzalez FJ, Kahn CR: Loss of ARNT/HIF1beta mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes. Cell 2005, 122:337-349.
• [80]Cheng K, Ho K, Stokes R, Scott C, Lau SM, Hawthorne WJ, O’Connell PJ, Loudovaris T, Kay TW, Kulkarni RN, Okada T, Wang XL, Yim SH, Shah Y, Grey ST, Biankin AV, Kench JG, Laybutt DR, Gonzalez FJ, Kahn CR, Gunton JE: Hypoxia-inducible factor-1alpha regulates beta cell function in mouse and human islets. J Clin Invest 2010, 120:2171-2183.
• [81]Ochiai D, Goda N, Hishiki T, Kanai M, Senoo-Matsuda N, Soga T, Johnson RS, Yoshimura Y, Suematsu M: Disruption of HIF-1alpha in hepatocytes impairs glucose metabolism in diet-induced obesity mice. Biochem Biophys Res Commun 2011, 415:445-449.
• [82]Yu J, Shi L, Wang H, Bilan PJ, Yao Z, Samaan MC, He Q, Klip A, Niu W: Conditioned medium from hypoxia-treated adipocytes renders muscle cells insulin resistant. Eur J Cell Biol 2011, 90:1000-1015.
• [83]Jiang C, Qu A, Matsubara T, Chanturiya T, Jou W, Gavrilova O, Shah YM, Gonzalez FJ: Disruption of hypoxia-inducible factor 1 in adipocytes improves insulin sensitivity and decreases adiposity in high-fat diet-fed mice. Diabetes 2011, 60:2484-2495.
• [84]Zhu Y, Lawton MT, Du R, Shwe Y, Chen Y, Shen F, Young WL, Yang GY: Expression of hypoxia-inducible factor-1 and vascular endothelial growth factor in response to venous hypertension. Neurosurgery 2006, 59:687-696. discussion 687-696
• [85]Narravula S, Colgan SP: Hypoxia-inducible factor 1-mediated inhibition of peroxisome proliferator-activated receptor alpha expression during hypoxia. J Immunol 2001, 166:7543-7548.
• [86]Kondo Y, Hamada J, Kobayashi C, Nakamura R, Suzuki Y, Kimata R, Nishimura T, Kitagawa T, Kunimoto M, Imura N, Hara S: Over expression of hypoxia-inducible factor-1alpha in renal and bladder cancer cells increases tumorigenic potency. J Urol 2005, 173:1762-1766.
• [87]Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Vasko J, Ljungberg B: The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 2005, 11:1129-1135.
• [88]Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, Belldegrun AS: Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 2007, 13:7388-7393.
• [89]Kim WY, Kaelin WG: Role of VHL gene mutation in human cancer. J Clin Oncol 2004, 22:4991-5004.
• [90]An J, Rettig MB: Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. Mol Cell Biol 2005, 25:7546-7556.
• [91]Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE: High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
• [92]Nicholson KM, Anderson NG: The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002, 14:381-395.
• [93]Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, Ahima RS, Guertin DA, Sabatini DM, Baur JA: Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012, 335:1638-1643.
• [94]Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, Wei Y, Sun HL, Li LY, Ping B, Huang WC, He X, Hung JY, Lai CC, Ding Q, Su JL, Yang JY, Sahin AA, Hortobagyi GN, Tsai FJ, Tsai CH, Hung MC: IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 2007, 130:440-455.
• [95]Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT: Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002, 22:7004-7014.
• [96]Liu L, Cash TP, Jones RG, Keith B, Thompson CB, Simon MC: Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol Cell 2006, 21:521-531.
• [97]Cancer Genome Atlas Research Network: Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013, 499:43-49.
• [98]Cheng T, Zhang JG, Cheng YH, Gao ZW, Ren XQ: Relationship between PTEN and Livin expression and malignancy of renal cell carcinomas. Asian Pac J Cancer Prev 2012, 13:2681-2685.
• [99]Merseburger AS, Hennenlotter J, Kuehs U, Simon P, Kruck S, Koch E, Stenzl A, Kuczyk MA: Activation of PI3K is associated with reduced survival in renal cell carcinoma. Urol Int 2008, 80:372-377.
• [100]Elfiky AA, Aziz SA, Conrad PJ, Siddiqui S, Hackl W, Maira M, Robert CL, Kluger HM: Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer. J Transl Med 2011, 9:133.